A 48-year-old man with bipolar I disorder has been stable on lithium carbonate 750 mg twice daily for 18 months. Routine monitoring shows: serum lithium 0.9 mEq/L, serum creatinine 1.6 mg/dL (baseline 0.8 mg/dL), eGFR 45 mL/min/1.73m², and fasting blood glucose 126 mg/dL. He reports polyuria (3–4 L/day) and polydipsia. Thyroid-stimulating hormone is 8.5 mIU/L (normal 0.4–4.0). Which of the following is the most appropriate next step in management?

Explanation

## Chronic Lithium Toxicity: Long-Term Adverse Effects **Key Point:** This patient has developed multiple organ-specific toxicities from chronic lithium exposure despite a therapeutic serum level (0.9 mEq/L). These are NOT acute toxicity but rather cumulative dose-dependent and idiosyncratic effects. ## Lithium's Chronic Organ Toxicity Profile | Organ System | Mechanism | Clinical Manifestation | Prevalence | Reversibility | |---|---|---|---|---| | **Kidney** | Chronic tubulointerstitial fibrosis; nephrogenic DI | Polyuria, polydipsia, rising Cr, CKD | 20–40% | Partial; Cr may not normalize | | **Thyroid** | Inhibition of thyroid peroxidase; iodine uptake ↓ | Hypothyroidism, goiter, elevated TSH | 20–30% | Reversible if lithium stopped early | | **Glucose metabolism** | Pancreatic beta-cell dysfunction; insulin resistance | Hyperglycemia, diabetes mellitus | 5–10% | May persist after lithium cessation | | **Parathyroid** | Increased PTH secretion (less common) | Hypercalcemia, nephrolithiasis | 5% | Reversible | **Clinical Pearl:** Lithium's nephrotoxicity is dose- and duration-dependent. The patient has: - Baseline Cr 0.8 → current 1.6 (doubled) - eGFR 45 (Stage 3b CKD) - Polyuria 3–4 L/day (nephrogenic DI) This pattern is pathognomonic for lithium-induced chronic kidney disease. Continuing the same dose will accelerate renal decline. ## Decision-Making Algorithm for Chronic Lithium Toxicity ```mermaid flowchart TD A["Chronic lithium use + organ dysfunction"]:::outcome --> B{"Therapeutic level?"}:::decision B -->|"Yes (0.6–1.2)"|C["Lithium-induced organ toxicity"]:::outcome B -->|"No"|D["Acute toxicity"]:::outcome C --> E{"Which organ affected?"}:::decision E -->|"Kidney (CKD, DI)"|F["Reduce dose 25–50%"]:::action E -->|"Thyroid (↑TSH)"|G["Add levothyroxine"]:::action E -->|"Glucose (hyperglycemia)"|H["Screen for diabetes"]:::action F --> I["Refer to nephrology"]:::action G --> I H --> I I --> J["Recheck labs in 4–6 weeks"]:::action J --> K{"Improvement?"}:::decision K -->|"Yes"|L["Continue reduced dose + monitoring"]:::action K -->|"No"|M["Consider alternative mood stabilizer"]:::action ``` **High-Yield:** Management of chronic lithium toxicity involves: 1. **Dose reduction** — Lower lithium dose (target level 0.5–0.7 mEq/L in CKD) to slow renal decline 2. **Hormone replacement** — Add levothyroxine for lithium-induced hypothyroidism (TSH 8.5 is elevated) 3. **Specialist referral** — Nephrology to stage CKD, monitor renal function, and assess need for alternative mood stabilizer 4. **Metabolic screening** — Fasting glucose 126 mg/dL is impaired fasting glucose; screen for diabetes 5. **Fluid management** — Adequate hydration (not fluid restriction) to minimize lithium reabsorption and support renal function **Mnemonic: LITHIUM CHRONIC TOXICITY WORKUP = KIDNEY-THYROID-GLUCOSE-PARATHYROID** - **K**idney: eGFR, Cr, urine osmolality, polyuria assessment - **T**hyroid: TSH, free T4 - **G**lucose: fasting glucose, HbA1c, diabetes screening - **P**arathyroid: serum calcium, PTH (if hypercalcemia suspected) **Warning:** Do NOT continue the same lithium dose in the setting of CKD — this accelerates renal decline. Do NOT increase the dose (option 4) — this worsens all organ toxicities. Desmopressin is NOT first-line for lithium-induced nephrogenic DI; adequate hydration and dose reduction are preferred. ## Monitoring Plan Post-Adjustment | Test | Baseline | After 4–6 weeks | Then | |---|---|---|---| | Serum lithium | 0.9 | Recheck (target 0.5–0.7 in CKD) | Every 3 months | | Serum Cr, eGFR | 1.6, 45 | Recheck | Every 3 months | | TSH, free T4 | 8.5, ? | Recheck after levothyroxine titration | Every 6–12 months | | Fasting glucose, HbA1c | 126, ? | Recheck | Every 6 months | | Urine osmolality | ? | Consider if DI persists | As needed | **Clinical Pearl:** Lithium-induced hypothyroidism is common and often asymptomatic (TSH elevation precedes symptoms). Levothyroxine replacement improves mood stability and may have neuroprotective effects. TSH should normalize to 0.5–2.5 mIU/L on replacement.